Inhibition of insulin‐like growth factor binding protein 5 proteolysis in articular cartilage and joint fluid results in enhanced concentrations of insulin‐like growth factor 1 and is associated with improved osteoarthritis
Open Access
- 7 March 2002
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 46 (3) , 694-703
- https://doi.org/10.1002/art.10222
Abstract
Objective The complement component C1s is present in dog joint fluid in an activated state. Since C1s degrades insulin-like growth factor binding protein 5 (IGFBP-5), we undertook to determine whether inhibiting C1s in joint fluid would result in an increase in the amount of intact IGFBP-5 and IGF-1 in cartilage and joint fluid, and whether C1s inhibition would be associated with a reduction in cartilage destruction during the development of osteoarthritis (OA). Methods Twenty-two dogs were randomized to 3 treatment groups. All dogs underwent anterior cruciate ligament transection and were exercised. Dogs received 1 of 3 treatments: buffer alone (controls; n = 6); PB-145, a peptide derived from the sequence of antithrombin III (n = 9); and pentosan polysulfate (PPS; n = 7). PB-145 or saline was injected into the joint space 3 times per week for 3 weeks. PPS was injected intramuscularly weekly for 3 weeks. Results Joint histology showed preservation of chondrocytes and a smooth joint surface in the animals treated with PB-145 and PPS. Mankin scoring showed statistically significant reductions in joint destruction with PB-145 and PPS treatments (P < 0.01) compared with buffer control. Mean active collagenase concentrations were decreased by these two treatments. Immunoblotting of joint fluid showed that both treatments increased concentrations of intact IGFBP-5. Direct analysis of IGFBP-3 and IGFBP-5 protease activity showed that IGFBP-5 was degraded more rapidly and that PB-145 and PPS inhibited the degradation of both proteins. Total IGF-1 concentrations in joint fluid were increased 5.6–5.8-fold by these two treatments. Analysis showed that C1s was being activated in joint fluid and that its activation was inhibited by the addition of PB-145 or PPS. Conclusion The findings suggest that direct inhibition of the serine protease C1s results in increased concentrations of intact IGFBP-5 and that proteolysis of IGFBP-3 is also inhibited, probably by the inhibition of some other protease. This increase in concentrations of intact IGFBP-3 and IGFBP-5 leads to an increase in IGF-1 which is associated with an improvement in joint architecture during the development of OA.Keywords
This publication has 45 references indexed in Scilit:
- The Complement Component C1s Is the Protease That Accounts for Cleavage of Insulin-like Growth Factor-binding Protein-5 in Fibroblast MediumJournal of Biological Chemistry, 2000
- The Insulin-like Growth Factors (IGFs) I and II Bind to Articular Cartilage via the IGF-binding ProteinsPublished by Elsevier ,2000
- Interleukin-1α and β in Growth Plate Cartilage Are Regulated by Vitamin D Metabolites In VivoJournal of Bone and Mineral Research, 1997
- Local disruption of the insulin‐like growth factor system in the arthritic jointArthritis & Rheumatism, 1996
- Mechanical behavior of articular cartilage in shear is altered by transection of the anterior cruciate ligamentJournal of Orthopaedic Research, 1995
- Mechanical Properties of Canine Articular Cartilage Are Significantly Altered Following Transection of the Anterior Cruciate LigamentJournal of Orthopaedic Research, 1994
- Treatment of canine osteoarthritis with insulin-like growth factor-1 (IGF-1) and sodium pentosan polysulfateOsteoarthritis and Cartilage, 1993
- Synthetic peptide inhibitors of complement serine proteases—III. Significant increase in inhibitor potency provides further support for the functional equivalence hypothesisMolecular Immunology, 1991
- Demonstration of type I and type II somatomedin receptors on bovine growth plate chondrocytesJournal of Orthopaedic Research, 1988
- Increased thymidine incorporation into fetal rat cartilage in vitro in the presence of human somatomedin, epidermal growth factor and other growth factorsJournal of Endocrinology, 1983